Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul J Farrell

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Plos Pathogens|July 28, 2018
A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infectionJillian A Bristol, Reza Djavadian, Emily R Albright, et al.
Journal of Virology|May 25, 2022
Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative DiseasesWiyada Wongwiwat, Benjamin Fournier, Irene Bassano, et al.
Cancer Cell|May 3, 2003
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosisDaniele Bergamaschi, Milena Gasco, Louise Hiller, et al.
Journal of Virology|March 20, 2015
Genome diversity of Epstein-Barr virus from multiple tumor types and normal infectionAnne L Palser, Nicholas E Grayson, Robert E White, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 15, 2021
Dual-Targeting Peptide-Guided Approach for Precision Delivery and Cancer Monitoring by Using a Safe Upconversion NanoplatformShuai Zha, Ho-Fai Chau, Wai Yin Chau, et al.
Plos Pathogens|February 15, 2020
B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infectionJames C Romero-Masters, Shane M Huebner, Makoto Ohashi, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Plos Pathogens|July 28, 2018
A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infectionJillian A Bristol, Reza Djavadian, Emily R Albright, et al.
Journal of Virology|May 25, 2022
Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative DiseasesWiyada Wongwiwat, Benjamin Fournier, Irene Bassano, et al.
Cancer Cell|May 3, 2003
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosisDaniele Bergamaschi, Milena Gasco, Louise Hiller, et al.
Journal of Virology|March 20, 2015
Genome diversity of Epstein-Barr virus from multiple tumor types and normal infectionAnne L Palser, Nicholas E Grayson, Robert E White, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 15, 2021
Dual-Targeting Peptide-Guided Approach for Precision Delivery and Cancer Monitoring by Using a Safe Upconversion NanoplatformShuai Zha, Ho-Fai Chau, Wai Yin Chau, et al.
Plos Pathogens|February 15, 2020
B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infectionJames C Romero-Masters, Shane M Huebner, Makoto Ohashi, et al.
Pageof 7